ArticleBMC pharmacology2003
Activity of opioid ligands in cells expressing cloned mu opioid receptors.
Article in BMC pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 106 citations in OpenAlex.
- Opioid and cocaine combined effect on cocaine-induced changes in HPA and HPG axes hormones in men.Pharmacology, biochemistry, and behavior · 2009Trial
- Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability.CNS neuroscience & therapeutics · 2024Review
- Dezocine as a potent analgesic: overview of its pharmacological characterization.Acta pharmacologica Sinica · 2022Review
- Incidence and risk factors of postoperative nausea and vomiting in lung cancer patients following lobectomy and application of analgesic pumps.The Journal of international medical research · 2022Article
- Effects of dezocine on morphine tolerance and opioid receptor expression in a rat model of bone cancer pain.BMC cancer · 2021Article
- In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances.Archives of toxicology · 2020Article
- Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a κ Partial Agonist and μ Partial Agonist.Scientific reports · 2018Article
- Additive analgesic effect of dexmedetomidine and dezocine administered intrathecally in a mouse pain model.Oncotarget · 2018Article
- Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys.The Journal of pharmacology and experimental therapeutics · 2018Article
- Dezocine exhibits antihypersensitivity activities in neuropathy through spinal μ-opioid receptor activation and norepinephrine reuptake inhibition.Scientific reports · 2017Article
- Article
- Differential Regulation of 6- and 7-Transmembrane Helix Variants of μ-Opioid Receptor in Response to Morphine Stimulation.PloS one · 2015Article
- Novel molecular targets of dezocine and their clinical implications.Anesthesiology · 2014Article
- The Anti-Nociception Effect of Dezocine in a Rat Neuropathic Pain Model.Translational perioperative and pain medicine · 2014Article
- Methadone but not morphine inhibits lubiprostone-stimulated Cl- currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl- currents.Cell biochemistry and biophysics · 2013Article
- Pharmacokinetics of non-intravenous formulations of fentanyl.Clinical pharmacokinetics · 2013Review
- Article
- Preoperative administration of intramuscular dezocine reduces postoperative pain for laparoscopic cholecystectomy.Journal of biomedical research · 2011Article
- Psychedelics and the human receptorome.PloS one · 2010Article
- Clinically relevant infusion rates of mu-opioid agonist remifentanil cause bradypnea in decerebrate dogs but not via direct effects in the pre-Bötzinger complex region.Journal of neurophysiology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe aim of the present study was to describe the activity of a set of opioid drugs, including partial agonists, in a cell system expressing only mu opioid receptors. Receptor activation was assessed by measuring the inhibition of forskolin-stimulated cyclic adenosine mono phosphate (cAMP) production. Efficacies and potencies of these ligands were determined relative to the endogenous ligand beta-endorphin and the common mu agonist, morphine.
resultsAmong the ligands studied naltrexone, WIN 44,441 and SKF 10047, were classified as antagonists, while the remaining ligands were agonists. Agonist efficacy was assessed by determining the extent of inhibition of forskolin-stimulated cAMP production. The rank order of efficacy of the agonists was fentanyl = hydromorphone = beta-endorphin > etorphine = lofentanil = butorphanol = morphine = nalbuphine = nalorphine > cyclazocine = dezocine = metazocine >or= xorphanol. The rank order of potency of these ligands was different from that of their efficacies; etorphine > hydromorphone > dezocine > xorphanol = nalorphine = butorphanol = lofentanil > metazocine > nalbuphine > cyclazocine > fentanyl > morphine >>>> beta-endorphin.
conclusionThese results elucidate the relative activities of a set of opioid ligands at mu opioid receptor and can serve as the initial step in a systematic study leading to understanding of the mode of action of opioid ligands at this receptor. Furthermore, these results can assist in understanding the physiological effect of many opioid ligands acting through mu opioid receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.